No particular dose adjustment advisable when tofacitinib coadministered with strong CYP2C19 inhibitors; decrease tofacitinib dose if coadministered with each reasonable CYP3A4 and potent CYP2C19 inhibitors .By means of this personalized solution, he identified his genetic weaknesses and was ready to improve his health 10X a lot better than he ever

Article Under Review